Literature DB >> 16709420

Pancreatitis associated with hyperlipoproteinaemia type I in mink (Mustela vison): earliest detectable changes occur in mitochondria of exocrine cells.

K Nordstoga1, B Christophersen, B Ytrehus, A Espenes, H Osmundsen, T Landsverk, T Olivecrona, G Olivecrona.   

Abstract

Pancreatic tissue from young mink homozygous for a mutation in the lipoprotein lipase gene was studied by light and electron microscopy, with the aim of describing the earliest detectable changes in a process which rapidly progresses into overt pancreatitis. The mutation leads to hyperlipoproteinaemia, corresponding to hyperlipoproteinaemia type I in man. Assessment of relevant hepatic and pancreatic enzymes were included in the investigation. The earliest detectable changes consisted of widespread swelling and vacuolation of exocrine cells, arising mainly from swollen mitochondria. To a lesser extent, vesiculation of endoplasmic reticulum occurred. Mitochondria exhibited various changes, including cavitation and dilution of the matrix, with shortened and disorganized cristae displaced towards the periphery. Lamellar figures that developed within mitochondria were numerous. Acinar lumina were somewhat dilated, while plasma membranes were relatively well preserved and secretory granules seemed unchanged. Exfoliative processes progressively occurred, resulting in total necrosis of groups of parenchymal cells, while intercalated ducts were spared. The necrosis was rapidly followed by inflammatory reactions. The activity of the mitochondrial enzyme carnitine O-palmitoyltransferase, essential for the transport of fatty acids into the mitochondria, was lower in the pancreas than in the liver. The activity of the peroxisomal fatty acid beta-oxidation was high in the liver and low in the pancreas of both lipoprotein lipase-deficient and control mink. It is concluded that pancreatic lesions associated with hyperlipoproteinaemia start in exocrine cells, and are most probably the result of a metabolic disturbance, possibly a toxic effect of an excess of free fatty acids.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16709420     DOI: 10.1016/j.jcpa.2006.01.003

Source DB:  PubMed          Journal:  J Comp Pathol        ISSN: 0021-9975            Impact factor:   1.311


  7 in total

1.  Potential influence of intravenous lipids on the outcomes of acute pancreatitis.

Authors:  Krutika S Patel; Pawan Noel; Vijay P Singh
Journal:  Nutr Clin Pract       Date:  2014-03-31       Impact factor: 3.080

Review 2.  Issues in hypertriglyceridemic pancreatitis: an update.

Authors:  John Scherer; Vijay P Singh; C S Pitchumoni; Dhiraj Yadav
Journal:  J Clin Gastroenterol       Date:  2014-03       Impact factor: 3.062

Review 3.  Hypertriglyceridemia Acute Pancreatitis: Animal Experiment Research.

Authors:  Lu Wang; Ting Xu; Ruifeng Wang; Xiaobing Wang; Dong Wu
Journal:  Dig Dis Sci       Date:  2021-05-03       Impact factor: 3.199

4.  Fatal hemorrhagic-necrotizing pancreatitis associated with pancreatic and hepatic lipidosis in an obese Asian palm civet (Paradoxurus hermaphroditus).

Authors:  Bongiovanni Laura; Di Girolamo Nicola; Montani Alessandro; Della Salda Leonardo; Selleri Paolo
Journal:  Asian Pac J Trop Biomed       Date:  2014-05

5.  Development of a novel model of hypertriglyceridemic acute pancreatitis in mice.

Authors:  Yiyuan Pan; Yong Li; Lin Gao; Zhihui Tong; Bo Ye; Shufeng Liu; Baiqiang Li; Yizhe Chen; Qi Yang; Lei Meng; Yuhui Wang; George Liu; Guotao Lu; Weiqin Li; Jieshou Li
Journal:  Sci Rep       Date:  2017-01-12       Impact factor: 4.379

6.  What may cause fetus loss from acute pancreatitis in pregnancy: Analysis of 54 cases.

Authors:  Min Tang; Jian-Ming Xu; Sha-Sha Song; Qiao Mei; Li-Jiu Zhang
Journal:  Medicine (Baltimore)       Date:  2018-02       Impact factor: 1.817

7.  Hypertriglyceridemia-Related Pancreatitis In Patients With Type 2 Diabetes: Links And Risks.

Authors:  Elad Shemesh; Barak Zafrir
Journal:  Diabetes Metab Syndr Obes       Date:  2019-10-07       Impact factor: 3.168

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.